Study on Mosunetuzumab and Polatuzumab Vedotin Compared to Rituximab with Gemcitabine and Oxaliplatin for Relapsed or Hard-to-Treat Aggressive B-Cell Non-Hodgkin's Lymphoma

Inclusion Criteria

• Must have a performance status score of 0, 1, or 2, indicating full activity or some restriction in strenuous activities.
• Have a type of aggressive lymphoma that tests positive for CD20, including specific subtypes like Diffuse Large B-Cell Lymphoma or Transformed Follicular Lymphoma.
• The cancer must have returned or not responded to at least one previous treatment.
• If only one previous treatment was received, the patient must not be eligible for a stem cell transplant.
• Must have measurable disease that can be tracked.
• Must have adequate liver, blood, and kidney function.
• Must have a creatinine clearance of at least 30 mL/min.
• Must test negative for HIV, or if positive, must be stable on treatment with a CD4 count of at least 200 and an undetectable viral load.

Exclusion Criteria

• Cannot be pregnant or breastfeeding, or planning to become pregnant during the study and for a specified time after the last dose of study drugs.
• Cannot have difficulty following study requirements.
• Cannot have had previous treatment with Mosunetuzumab, Polatuzumab Vedotin, or similar drugs.
• Cannot have severe nerve damage or persistent side effects from previous cancer treatments.
• Cannot have received certain cancer treatments within a specified time before starting the study.
• Cannot have had a stem cell transplant or CAR T-cell therapy recently.
• Cannot have had a solid organ transplant.
• Cannot have a history of certain severe immune system reactions or other cancers that could interfere with the study.
• Cannot have current or past central nervous system involvement with lymphoma or certain brain diseases.
• Cannot have significant heart or lung disease.
• Cannot have active infections or certain viral infections.
• Cannot have had major surgery recently.
• Cannot have received a live vaccine recently.
• Cannot have tested positive for COVID-19 recently.
• Cannot have a history of autoimmune disease or significant liver disease.
• Cannot have participated in another clinical trial recently.